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RESEARCH IN CONTEXT 
 
Evidence before this study 
We searched PubMed, Embase and Web of Science for relevant articles on 12 
September 2018 with search terms “stroke”, “cerebrovascular accident”, “nitric oxide 
donor”, and “randomised controlled trial”. We also manually searched original articles 
and reviews in our own references library. Searches were restricted to completed 
trials in human beings with abstracts or full texts published and relating to 
administration of glyceryl trinitrate (GTN, nitroglycerin) within 6 hours of stroke onset, 
and where information on functional outcome and death was available. When 
combining results from two randomised controlled patient-masked trials with blinded-
outcome assessment, one a pilot ambulance-based study and the other a pre-
specified subgroup of a large hospital-based trial, treatment with GTN within the first 
6 hours of stroke onset was associated with less death, and reduced death or 
dependency, both overall and separately in ischaemic stroke and intracerebral 
haemorrhage. 
 
Added value of this study 
Ultra-acute administration of GTN in the ambulance within 4 hours of stroke onset did 
not alter functional outcome in patients suspected to have a stroke. It was feasible for 
UK paramedics to recruit, obtain consent and treat stroke patients in the pre-hospital 
environment. 
 
Implications of all the evidence 
We did not find evidence that ultra-early administration of transdermal glyceryl 
trinitrate improves functional outcome or reduces death in patients with suspected 
ultra-acute stroke. Large paramedic-delivered trials are possible in the UK. 
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SUMMARY 
 
Background 
Transdermal glyceryl trinitrate (GTN, nitroglycerin), a nitric oxide donor, may improve 
outcome when administered very early after stroke onset. 
 
Methods 
We undertook a multicentre paramedic-delivered ambulance-based prospective 
randomised sham-controlled blinded-endpoint trial in adults with presumed stroke 
within 4 hours of onset. Participants were randomised 1:1 to receive transdermal GTN 
(5 mg daily) or a similar sham dressing in the ambulance, and continued this for three 
days in hospital. The primary outcome was the 7-level modified Rankin Scale (a 
measure of functional outcome) at 90 days assessed by central telephone follow-up 
with blinding to treatment. Analysis was hierarchical, first in participants with a 
confirmed stroke or transient ischaemic attack (TIA), and then in all who were 
randomised (intention-to-treat) according to the statistical analysis plan. This trial is 
registered, ISRCTN26986053. 
 
Findings 
1149 participants (GTN 568, sham 581) were recruited by 516 paramedics from 8 UK 
ambulance services (October 2015 - May 2018). The median time to randomisation 
was 71 minutes [interquartile range 45, 116] and the final diagnosis of the index 
event: ischaemic stroke 597 (52%), intracerebral haemorrhage 145 (13%), TIA 109 
(9%), and stroke/TIA mimic 281 (26%). GTN lowered blood pressure by 5·8/2·6 
mmHg (p<0·001) at hospital admission compared with sham. There was no difference 
in the modified Rankin Scale in participants with a final diagnosis of stroke or TIA: 
GTN 3 [2, 5; n=420] vs sham 3 [2, 5; n=408], adjusted common odds ratio for poor 
outcome, acOR 1·25 (95% confidence interval, CI 0·97–1·60; p=0·083), or in all 
patients (GTN 3 [2, 5] vs sham 3 [2, 5]), acOR 1·04 (95% CI 0·84–1·29; p=0·69). 
There was no difference for secondary outcomes, death or serious adverse events. 
 
Interpretation 
Pre-hospital treatment with transdermal GTN does not appear to improve functional 
outcome in patients with presumed stroke. It is feasible for UK paramedics to obtain 
consent and treat stroke patients in the ultra-acute pre-hospital setting. 
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FUNDING 
Funded by British Heart Foundation 
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BACKGROUND 
 
High blood pressure (BP) is common in acute stroke and a predictor of poor outcome; 
however, large trials of BP-lowering have given variable results, and the management 
of high BP in ultra-acute stroke remains unclear 1 although lowering BP in 
intracerebral haemorrhage (ICH) is recommended in hospital.2 Nitric oxide (NO) 
donors are candidate treatments for acute stroke because of their cerebral and 
systemic vasodilatory properties, the latter leading to a reduction in BP. Preclinical 
stroke studies found that NO donors improved regional cerebral blood flow and 
reduced stroke lesion size if administered rapidly.3,4 Further, vascular NO levels are 
low in acute stroke and are associated with a poor outcome 5,6 raising the possibility 
that supplementing NO would be beneficial. 
 
Five randomised trials of transdermal glyceryl trinitrate (GTN, a NO donor) in acute 
stroke showed that GTN lowered peripheral and central BP, 24 hour BP, pulse 
pressure and augmentation index.7-11 In contrast, GTN had no effect on middle 
cerebral artery blood flow velocity, cerebral blood flow, intracranial pressure, or 
platelet function.7-9 Although four of the trials were neutral for functional outcome,7-
9,11 GTN improved functional outcome in the phase II Rapid Intervention with Glyceryl 
trinitrate in Hypertensive stroke Trial (RIGHT, with randomisation by paramedics 
within four hours of stroke),10 and a pre-specified subgroup analysis of the phase III 
hospital-based Efficacy of Nitric Oxide in Stroke trial (ENOS, with randomisation within 
six hours of stroke).11,12 Summary and individual patient data meta-analyses of these 
five trials suggested that very early administration of GTN (312 patients within 6 
hours of onset) was beneficial in both ischaemic stroke (IS) and ICH, and reduced 
death, disability, cognitive impairment, mood disturbance and poor quality of life.13,14 
Beyond 6 hours, treatment effects were neutral. 
 
For stroke interventions that do not require prior neuroimaging and that may have 
benefit in both IS and ICH, treatment prior to hospital admission will reduce time to 
initiation of treatment. The Field Administration of Stroke Therapy – Magnesium 
(FAST-MAG) ambulance-based stroke trial successfully recruited 1700 patients in the 
USA,15 but no prior large prehospital stroke trials have been completed in the UK.  
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We performed the phase III Rapid Intervention with Glyceryl trinitrate in Hypertensive 
stroke Trial-2 (RIGHT-2) trial to assess two questions: first, to determine the safety 
and efficacy of GTN when given very early after presumed stroke onset by paramedics 
prior to hospital admission; and second, to assess feasibility of performing a large 
multicentre ambulance-based paramedic-delivered trial in patients with presumed 
stroke in the UK. 
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METHODS 
 
Study design 
RIGHT-2 was a pragmatic multicentre paramedic-delivered ambulance-based 
prospective randomised sham-controlled participant- and outcome-blinded trial in 
adult participants with ultra-acute presumed stroke within 4 hours of onset in the UK. 
Details of the design, statistical analysis plan and baseline data, have been 
published,16-18 and the design and protocol are summarised in the Appendix. The 
protocol is available at: http://right-2.ac.uk/docs/protocol50 
 
Study population 
Adult patients were eligible for inclusion following an emergency ‘999’ telephone call 
for presumed stroke if they presented within 4 hours of onset of their symptoms to a 
trial-trained paramedic from a participating ambulance service and could be taken to a 
participating hospital. Patients had to have a Face-Arm-Speech-Time (FAST) score of 
two or three (thus ensuring the presence of a motor weakness), and a systolic blood 
pressure (SBP) >120 mmHg. Patients from a nursing home, or with reduced 
consciousness (Glasgow Coma Scale score, GCS <8/15), hypoglycaemia (capillary 
glucose <2.5 mmol/l), or a witnessed seizure, were excluded (see Appendix for a full 
listing of the inclusion and exclusion criteria). 
 
Paramedics managed the primary consent process, and patients with capacity gave 
written informed consent that covered the whole trial. If capacity was absent, proxy 
consent was obtained from an accompanying relative, carer or friend if present, or 
from the paramedic if no accompanying person was present (as done in RIGHT).10 
Confirmatory consent was obtained from the patient, or their relative, carer or friend 
(if available) in hospital when the patient lacked capacity in the ambulance. 
 
The final diagnosis was made after arrival at hospital by the principal investigator 
based on clinical and neuroimaging findings and was categorised as ICH, IS, transient 
ischaemic attack (TIA), or non-stroke/TIA mimic. 
 
Randomisation and masking 
Patients were randomly assigned, in 1:1 ratio, to receive transdermal glyceryl 
trinitrate (also known as nitroglycerin; 5 mg as Transiderm-Nitro® 5, Novartis, 
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Frimley UK) or a similar-appearing sham skin dressing (DuoDERM® hydrocolloid 
dressing, Convatec, Flintshire UK). Randomisation was stratified by ambulance station 
with blocks of 4 packs (2 active, 2 control) in random permuted order. Each treatment 
pack was sealed to maintain blinding of paramedics. Ambulances carried only one 
pack at a time - paramedics signed-out the treatment pack with the lowest 
randomisation number from their ambulance station at the start of shift and returned 
it if unused at end of shift. Opened but unused packs were returned to the 
Coordinating Centre. GTN patches/sham dressings came in marked sealed sachets so 
paramedics and nurses doing medication rounds in hospital knew treatment 
assignment. However, participants were effectively masked since the 
patches/dressings themselves were unlabelled, and a gauze dressing was taped over 
the top of the patch/dressing to provide additional blinding. 
 
Treatment and follow-up in hospital 
The first treatment (GTN or sham) was administered by the paramedic immediately 
after randomisation in the ambulance, and further treatments were given for up to 
three days whilst in hospital. Patches/dressings were placed on the shoulder or back, 
and the site changed daily. 
 
Ambulance data (pre- and post-first-treatment), and hospital-collected clinical and 
neuroimaging data at admission (post-first-treatment), day 4 (end-of-treatment) and 
on death or discharge, were entered on-line into a secure web-based database system 
(https://nottingham.ac.uk/~nszwww/right-2/live/right-2_login.php). These data were 
validated and used to confirm the patient’s eligibility. 
 
Outcome measures 
The primary outcome was functional outcome assessed with the 7-level modified 
Rankin Scale (mRS) measured at 90 days after randomisation.19 mRS scores range 
from 0 to 6, with a score of 0 and 1 indicating no or some symptoms, respectively, 2-
5 indicating increasing levels of disability/dependency, and 6 death. Outcomes were 
recorded centrally by telephone by a trained assessor masked to treatment allocation; 
to ensure reliable scoring, raters used a structured questionnaire.20 If the participant 
could not be contacted by telephone (after multiple attempts), a questionnaire 
covering the same outcome measures was sent by post. The primary analysis involved 
a comparison of the distribution of all 7 levels of the mRS (shift) between the 
treatment groups.21 
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Participants were seen at day 4 (or at discharge if earlier) to determine adherence to 
treatment and assess neurological deterioration (increase in the National Institutes of 
Health stroke scale, NIHSS, by at least 4 points from hospital admission to day 4 
and/or worsening conscious level in the NIHSS consciousness domain item Ia). At 
discharge from hospital, duration of stay, and discharge destination (to institution or 
home), were recorded. Pre-specified secondary outcomes at day 90 included activities 
of daily living (Barthel Index, BI); cognition (modified telephone Mini-Mental State 
Examination, t-MMSE; Telephone Interview for Cognition Scale-modified, TICS-M; 
categorical verbal fluency (using animal naming); health-related quality of life 
(European Quality of Life-5 dimensions-3 level, EQ-5D-3L, from which Health Status 
Utility Value, HSUV, was calculated; and EQ-visual analogue scale, EQ-VAS); and 
mood (abbreviated Zung depression score, ZDS), all as used in ENOS.11 
 
Safety outcomes included all-cause and cause-specific case fatality; hypotension or 
hypertension occurring during the first 4 days (as reported by investigators); and 
serious adverse events (SAEs, all up to day 5, and fatal from day 5). SAEs were 
validated and categorised by expert adjudicators who were blinded to treatment 
assignment. 
 
Plain brain scans (computerised tomography [CT] or magnetic resonance [MR] 
imaging) performed on arrival at hospital, were collected for central adjudication by 
expert neuroradiologists using assessments updated from ENOS.11 Depending on local 
practice, CT/MR angiography was also performed and adjudicated centrally (see 
Appendix for more information). Imaging outcomes on admission to hospital included 
infarct extent (IST-3 score, Alberta Stroke Program Early CT Score, ASPECTS), 
presence of hyperdense artery, haemorrhagic transformation, and mass effect 
including midline shift for participants with IS; haematoma location, size, volume, 
extension (to subarachnoid spaces or ventricles) and mass effect including midline 
shift for ICH, and type and location of mimics. On the next day, a research CT or MR 
scan was performed to assess safety; the same factors were assessed as above for IS 
and ICH.22 
 
Study oversight 
The trial was conceived and designed by the grant applicants, and they wrote the 
protocol. The study was approved by the UK regulator (Medicines & Healthcare 
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products Regulatory Agency, ref: 03057/0064/001-0001; Eudract 2015-000115-40) 
and national research ethics committee (IRAS: 167115), and was adopted by the 
National Institute for Health Research Clinical Research Network. The trial was 
overseen by a Trial Steering Committee (which included three independent members 
and a patient-public representative), and advice given by an International Advisory 
Committee. The day-to-day conduct of the trial was run by a Trial Management 
Committee which was based at the Stroke Trials Unit in Nottingham. An independent 
Data Monitoring Committee reviewed unblinded data every 6 months and performed a 
formal interim analysis midway through the trial (see Supplement for description of 
the stopping rules); this analysis was performed after 714 patients had been recruited 
and followed-up at 90 days and the DMC recommended that the trial should continue. 
Study data were collected and quality-assured by the RIGHT-2 Coordinating Centre in 
Nottingham. Analysis, interpretation, and report writing were performed 
independently of the funder and sponsor. The corresponding author wrote the first 
draft of the manuscript, and this was edited and commented on by the writing 
committee, all of whom approved the decision to submit the manuscript for 
publication. 
 
Statistical analysis 
A total sample size of 850 participants (425 in each arm) was required to detect a 
shift in mRS with a common odds ratio of 0·70.17 This assumed an overall significance 
level of 5%, 90% power, distribution of mRS scores as shown in the Appendix,23 3% 
loss to follow-up, mimic and TIA rate of 20%, and reduction for baseline co-variate 
adjustment of 20%.24 During the trial, the non-stroke diagnosis rate was noted to 
exceed 30%. Since this would reduce the number of participants recruited with a 
stroke diagnosis, and therefore the statistical power in this group, the overall sample 
size was increased from 850 to 1050 to maintain the overall effect size and statistical 
power. Further, a decision was made by the Trial Steering Committee to perform a 
hierarchical analysis, this comprising a sequential analysis performed in two 
progressively inclusive cohorts based on the final in-hospital diagnosis: participants 
with confirmed stroke or TIA (cohort 1/target disease population); and stroke, TIA, or 
non-stroke/TIA (mimic), i.e. all patients (cohort 2/intention-to-treat, ITT). Further 
information is given in the Appendix. 
 
The primary outcome was assessed using ordinal logistic regression with adjustment 
for age, sex, premorbid mRS, FAST score, baseline SBP, index event (ICH, IS, TIA, 
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mimic), time to randomisation, and reperfusion treatment (thrombectomy, alteplase, 
none).17 The assumption of proportional odds was tested using the likelihood ratio 
test. Heterogeneity of the treatment effect on the primary outcome was assessed in 
pre-specified subgroups by adding an interaction term to an adjusted ordinal logistic 
regression model. An unadjusted and per protocol (as defined in the appendix) 
analysis is shown for completeness. Death was analysed using Kaplan-Meier and 
adjusted Cox regression models. Other outcomes were assessed using adjusted binary 
logistic regression (neurological deterioration, headache, hypotension, hypertension, 
feeding status, disposition, death in hospital), Cox regression (death), ordinal logistic 
regression (mRS, disposition), multiple linear regression (NIHSS, length of stay in 
hospital, t-MMSE, TICS-M, animal naming, ZDS, EQ-5D HSUV EQ-VAS) and analysis of 
covariance (blood pressure). A global outcome (comprising ordered categorical or 
continuous data for mRS, BI, ZDS, TICS-M and EQ-5D-HSUV) was analysed using the 
Wei-Lachin test.25 Participants who did not receive their assigned treatment, who did 
not adhere to the protocol, or who had a stroke mimic were all still followed up in full 
at day 90 and are included in the main analyses. No adjustments were made for 
multiplicity of testing since all secondary analyses were hypothesis-generating and 
designed to support the primary analysis. Data are shown as number (%), median 
[interquartile range], mean (standard deviation), and odds ratio, hazard ratio, 
difference in means or Mann-Whitney difference (global) with 95% confidence 
intervals. Primary analyses were done as randomised (cohort 2) using observed 
outcome data only, and performed with SAS software (version 9.4). In sensitivity 
analyses, we performed a per-protocol analysis, and missing mRS data were imputed 
using multiple regression-based imputation. 
 
Role of the funding source 
The trial was funded by the British Heart Foundation (CS/14/4/30972) and sponsored 
by the University of Nottingham. There was no commercial support for the trial, and 
GTN patches and sham dressings were sourced by the Pharmacy at Nottingham 
University Hospitals NHS Trust. The funder did not contribute to data collection, 
analysis, interpretation, manuscript writing or decision to submit. The corresponding 
author and two statisticians (PS, LJW) had full access to all the data in the study; 
additionally, the corresponding author had final responsibility for the decision to 
submit for publication and is the guarantor for the trial. 
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RESULTS 
 
Study population 
Between 22 October 2015 and 23 May 2018 (appendix Table 1), a total of 1149 
participants (cohort 2) were enrolled (568 randomised to GTN patch and 581 to sham 
dressing, CONSORT diagram, Figure 1) by 516 (of 1492, 35%) trial-trained 
paramedics based at 184 ambulance stations in 8 (of 13, 62%) ambulance services in 
England and Wales; these participants were taken to 54 hospitals. For logistical 
reasons, screening logs were not kept. All patients had consent in the ambulance, this 
being obtained from 603 (53%) patients; 429 (37%) relatives, carers or friends; and 
117 (10%) paramedics. The CONSORT diagram for all stroke/TIA (cohort 1) is shown 
in appendix Figure 1. Demographic and clinical characteristics were similar in the two 
treatment groups across the whole trial population and in patients with stroke or TIA 
(Table 1). The mean age was 72·5 (standard deviation 14·6) years, women comprised 
48% of the participants, 60% of participants had a maximum FAST score=3, and 26% 
a GCS <14. The final diagnosis of the qualifying event was: IS 52%, ICH 13%, TIA 
9% and a stroke/TIA-mimicking condition 26%. Common causes of stroke mimics 
included seizure (18%), migraine (17%) and functional symptoms (15%). 
 
Time intervals 
The median time from the onset of symptoms to randomisation was 71 minutes 
[interquartile range, 45, 116] and to start of study drug 73 [48, 118] minutes. 
Overall, study drug was received within 30, 60 and 120 minutes of symptom onset in 
59 (5%), 439 (38%) and 865 (75%) of participants respectively. 
 
Adherence and protocol violations 
Adherence to the first randomised treatment was excellent in both the confirmed 
stroke/TIA group (cohort 1/target disease population, 849, >99%) and in all 
participants (cohort 2/ITT, 1144, >99%) (appendix Table 2, appendix Figure 1). In 
the per protocol definition of adherence, which required that at least the first two 
doses of treatment were received, only 571 (67%) of cohort 1 and 631 (55%) of 
cohort 2 were adherent; common reasons for non-adherence were a diagnosis of a 
non-stroke, early discharge, a medical decision to stop randomised treatment, a 
procedural error, or missing trial medication (appendix Table 2). Just 382 (45%) of 
participants with a stroke or TIA (cohort 1), and 408 (36%) of participants overall 
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(cohort 2), received all four days of treatment. 
 
There were 38 protocol violations in the ambulance and these mainly comprised 
inclusion of patients beyond 4 hours, FAST score <2, SBP <120 mmHg, or from a 
nursing home (appendix Table 8). The most common protocol violations in hospital 
involved not administering the second day’s treatment, or failure to obtain secondary 
consent. 
 
Blood pressure treatment and achieved blood pressure levels 
In the target population of stroke or TIA, BP at baseline was 163·2 (24·7)/91·9 (18·5) 
mmHg (Table 1) and fell in both GTN and sham groups over the 4 days following 
randomisation (appendix Figure 2). Following the treatment, systolic and diastolic BP 
were lower in the GTN group by 5·8/2·6 mmHg (p<0·0001/p=0·0026) at hospital 
admission, and 5·3/2·6 mmHg (p =0·0002/p=0·0054 at day 2, as compared with 
sham. The difference in BP between the GTN and sham groups then diminished with 
no difference at days 3 and 4. Similar findings were seen for the effect of GTN on BP 
in all patients (cohort 2, appendix Figure 3). In all patients, symptomatic hypotension 
was more common with GTN (21 [4%] vs 9 [2%], adjusted odds ratio, aOR 2·49, 
95% CI 1·11, 5·57; p=0·026) (Table 2). Heart rate did not differ between the 
treatment groups (data not shown). 
 
Primary outcome 
Vital status and mRS were available in 1122 (98%) and 1102 (96%) participants 
respectively (Figure 1); there was no differential loss to follow-up or withdrawals 
between the treatment groups. Blinding was maintained with participants unable to 
identify which medication they had received (appendix Table 3).  
 
In the cohort of confirmed stroke and TIA (cohort 1/target disease population), there 
was no strong evidence of an effect of GTN on functional outcome at 90 days in 
comparison with sham (GTN 3 [2, 5] vs sham 3 [2, 5], acOR 1·25, 95% CI 0·97–1·60, 
p=0·083; Table 2, Figure 2); the acOR 1·25 suggests a tendency in favour of sham 
treatment. In sensitivity analyses, there was no difference in mRS when compared as 
mean difference, proportions with poor outcome (mRS>2), mRS in the per protocol 
population, or when data were imputed for participants without a recorded mRS at 
day 90 (Table 2). A significant interaction of the effect of GTN on mRS was present for 
time to randomisation with a negative effect of GTN apparent in those participants 
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recruited within one hour of symptom onset (Figure 3); no other significant effect 
modification by subgroups was detected. Post hoc assessment of the treatment effect 
on mRS in clinically relevant subgroups defined on or after admission to hospital (i.e. 
potentially affected by treatment) showed a significant interaction with a worse 
outcome in patients with a more severe stroke on admission to hospital (post-
treatment NIHSS >12) (appendix Figure 4). 
 
When assessed in components of the target population (cohort 1/target disease 
population), mRS did not differ between GTN and sham in participants with stroke 
(GTN 3 [2, 6] vs sham 3 [2, 5], acOR 1·26, 95% CI 0·96, 1·64; p=0·095; N=722), 
ischaemic stroke (GTN and Sham median score 3 IQR [2, 5], acOR 1·15, 95% CI 
0·85, 1·54; p=0·36; N=580), or TIA (GTN median 3 IQR [1, 3] versus Sham 2 [1, 3], 
acOR 1·57, 95% CI 0·74, 3·35; p=0·24; N=105). However, GTN was associated with 
a non-significantly worse outcome in patients with a final diagnosis of ICH (GTN 
median 5 IQR [4, 6] versus Sham 5 [3, 5], acOR 1·87, 95% CI 0·98, 3·57; p=0·057; 
N=142; appendix Figure 6). 
 
The analysis of all patients in the trial (cohort 2/ITT) also showed that mRS did not 
differ between GTN and sham in the primary analysis (median for both groups 3, IQR 
[2, 5], acOR 1·04, 95% CI 0·84–1·29, p=0·69; Table 2, appendix Figure 5) or in any 
sensitivity analysis (data not shown). In pre-defined subgroups, there was a 
significant interaction by final diagnosis (appendix Figure 6); in contrast to the effect 
of GTN in stroke or TIA (see above), GTN appeared to be associated with an improved 
mRS in patients with a mimic (non-stroke/TIA) (GTN and Sham median score 3 IQR 
[1, 4], acOR 0·54, 95%CI 0·34–0·85, p=0·008); in a post hoc analysis, this positive 
finding was not localised to any particular type of mimic (data not shown). 
 
Secondary outcomes 
GCS at admission to hospital was 0·4 point lower in patients randomised to GTN. 
Because of this difference, we performed a post hoc sensitivity analysis adding 
baseline GCS to the statistical model for the primary outcome in cohort 1; this had 
minimal effect on the result, OR 1·22 (95% CI 0·95, 1·56). Otherwise, there was no 
evidence of any other differences between GTN and sham in secondary outcomes in 
the cohort of participants with confirmed stroke/TIA (Table 2, appendix Table 4). A 
global analysis encompassing the primary outcome and pre-specified secondary 
outcomes showed no difference (Table 2, appendix Figure 7). 
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As compared to sham, patients with an ischaemic stroke who were randomised to 
GTN were less likely to have thrombectomy (appendix Table 5); conversely, patients 
receiving GTN were more likely to be ventilated on an intensive care unit. Use of other 
standard stroke treatments did not differ between the randomised treatment groups. 
 
There were no differences between GTN and sham in secondary outcomes at day 90 
(Table 2). 
 
Safety 
The proportion of deaths at day 4 did not differ between GTN and sham either in the 
target confirmed stroke/TIA population (cohort 1) or in the full ITT population (Table 
2). Similarly, the proportion of deaths by day 90 did not differ in the target confirmed 
stroke/TIA population (cohort 1; aHR 1·24, 95% CI 0·91–1·68, p=0·17; Table 2, 
appendix Figure 8) and all population (cohort 2; Table 2, appendix Figure 9). The 
commonest causes of death were progression or recurrence of the index stroke, and 
pneumonia. A slight excess of headaches by day 4 was apparent for GTN. The number 
of participants experiencing one or more SAEs did not differ between the GTN and 
sham groups (188 [33%] vs 170 [29%), p=0·16; appendix Table 6) although 
cardiovascular SAEs were more common with GTN. No suspected unexpected serious 
adverse reactions (SUSAR) occurred. 
 
Imaging outcomes 
The on-treatment hospital-based imaging findings for participants with a final 
diagnosis of stroke or TIA are shown in appendix Table 7. In ischaemic stroke, 
scanning was performed on admission and day 2 at 2·2 hours and 27·7 hours, 
respectively, after the onset after stroke or TIA. There were no differences between 
GTN and sham in respect of infarct size, swelling or mass effect on plain brain CT. 
Patients receiving intravenous thrombolysis were non-significantly less likely to have 
haemorrhagic transformation with GTN as compared with sham: 5 (3%) vs 11 (8%), 
OR 0·38 (95% CI 0·13, 1·13; p=0·082). For participants with ICH, scanning was 
performed on admission at an average of 2·3 hours and 28·9 hours after the onset 
after stroke or TIA (appendix Table 7). In comparison with sham, GTN was associated 
with larger haematoma (OR 1·95, 95% CI 1·07, 3·58; p=0·030) and more mass effect 
(OR 2·42, 95% CI 1·26, 4·68; p=0·0083) at hospital admission. 
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Meta-analysis of completed trials 
Addition of the results for participants with confirmed stroke/TIA (cohort 1/target 
disease population) in RIGHT-2 to the positive published Cochrane review for hyper-
acute administration of GTN 14 resulted in neutral effects for end-of-trial death or 
dependency (mRS>2), OR 0·80 (95% CI 0·59–1·10; p=0·17; heterogeneity I2 16%, 
p=0·30) and death, OR 0·52 (95% CI 0·16–1·72; p=0·28; heterogeneity I2 86%, 
p=0·0007) (appendix Figure 10). Heterogeneity between trial results was apparent for 
death emphasising the difference between the results for RIGHT-2 versus the earlier 
RIGHT and ENOS-early trials. 
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DISCUSSION 
 
RIGHT-2 recruited 1149 patients from 8 UK ambulance services and these were taken 
to 54 hospitals; 516 paramedics from 184 ambulance stations performed screening 
and consent, and delivered treatment and early follow-up measurement. Consent or 
proxy consent was obtained from patients; relatives, carers or friends of the patient; 
or by the recruiting paramedic. Treatment was commenced very early, and faster than 
in hospital-based trials, with 38% of patients treated in the first 60 minutes after 
stroke onset (‘golden hour’ 26). Hence, we have confirmed that it is feasible to perform 
a large multicentre paramedic-delivered ambulance-based trial in patients with 
suspected stroke in the UK in patients with suspected stroke. Having confirmed 
feasibility, we compared the effect of GTN with sham and found that treatment with 
GTN did not influence functional outcome in patients with the target diagnosis of 
confirmed stroke or TIA, or in the overall recruited population. 
 
The results for GTN differ from those reported in a previous small phase II 
ambulance-based trial (RIGHT, with recruitment within 4 hours of onset) and a 
subgroup of a large phase III trial (ENOS, recruitment <6 hours of onset).10,12 There 
are several potential explanations for these discrepant results. First, GTN may simply 
be ineffective in very early stroke, as suggested by the absence of any effect of GTN 
on multiple secondary outcomes and a global outcome, and neutral meta-analyses 
when combining ENOS-early, RIGHT and RIGHT-2. Second, the discrepant findings 
may be due to chance rather than any true positive or negative effect of GTN. Chance 
may also account for the observation that GTN appeared to be beneficial in 
participants with a final diagnosis of non-stroke/TIA irrespective of the underlying 
mimic diagnosis. Third, the difference between RIGHT-2 and ENOS-early/RIGHT may 
be real due to intrinsic differences in their design: RIGHT-2 randomised patients far 
earlier (median 71 minutes) than in RIGHT and ENOS-early combined (median 257 
minutes) and so will have recruited a different cohort of patients; as compared with 
these earlier trials, participants in RIGHT-2 were older, and more likely to have pre-
morbid dependency, diabetes, previous stroke, and ischaemic heart disease; and, 
among the ICH patients, more likely to still be in a period of hematoma expansion. All 
these factors may have contributed to different effects of GTN on functional outcome, 
as was apparent for reductions in systolic BP (6·2 mmHg in RIGHT-2 vs. 9·4 mmHg in 
ENOS-early). Last, studies showing a positive effect of GTN within 6 hours used a 7-
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day treatment period and had higher rates of adherence so it is conceivable that GTN 
was not given for long enough in RIGHT-2. 
 
Although RIGHT-2 was a neutral trial, GTN was associated with a tendency for a 
worse functional outcome in confirmed stroke/TIA patients (cohort 1), with a 95% 
confidence interval covering a range from a clinically insignificant benefit (OR 0·97) to 
a clinically significant hazard (OR 1·60). This tendency towards harm was particularly 
seen in patients with ICH, very early stroke (<1 hour) and severe stroke (GCS<12, 
NIHSS>12). Further, the imaging findings support a negative effect of GTN in ultra-
acute ICH with larger haematoma, and more haematoma expansion, perihaematoma 
oedema, mass effect, and mid-line shift. A number of explanations might explain 
potential hazard in ICH, which has a higher base rate of ultra-early neurological 
deterioration than IS,27 and these are given in decreasing order of likelihood. First, the 
earliest stage in haemostasis is vasoconstriction and GTN may prevent this protective 
response and so lead to very early haematoma expansion. Second, although we did 
not identify antiplatelet effects with GTN in a previous study of patients with stroke,7 
others have reported this in laboratory experiments 28 and GTN could therefore have 
amplified haematoma expansion in ICH thereby countering any effects of lowering BP. 
Third, venodilators such as sodium nitroprusside and GTN have been shown 
experimentally and clinically to raise intracerebral pressure (ICP) and reduce cerebral 
blood flow, particularly if ICP is already elevated.29,30 Reduced blood flow might then 
induce peri-haematoma ischaemia. Although pilot work did not find a negative effect 
of GTN on CBF or cerebral perfusion pressure in hospitalised patients with recent 
stroke,8,9,31 these studies were not in the ultra-acute period after stroke and were 
mainly in ischaemic stroke and so may not be directly relevant to the RIGHT-2 
population. Last, GTN can stimulate the formation of reactive oxygen species such as 
superoxide (O2-) and peroxynitrite (OONO-) and these can attenuate vasodilation and 
increase the potential for cellular damage.32 
 
Preclinical studies of neuroprotective and collateral enhancement therapy in ischaemic 
stroke suggest that treatment is most effective when administered rapidly after 
symptom onset. Ideally treatment would be started prior to hospital admission to 
reduce “stroke-to-needle” time.33 The US FAST-MAG trial successfully randomised 
1700 participants in ambulances to receive intravenous magnesium or placebo within 
2 hours of symptom start, and took them to 36 hospitals.15 RIGHT-2 extends these 
observations demonstrating that a large stroke ambulance trial can be performed 
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embedded in the UK national health service involving multiple ambulance services and 
hospitals. Hence, other interventions that do not require prior CT scanning could be 
tested in this environment in the future. By extrapolation, paramedics will also be able 
to administer such interventions routinely in the ambulance once they have been 
shown to be effective in one or more types of stroke, and safe in mimics. 
 
The present trial has several strengths, including the large sample size; 
generalisability due to wide inclusion criteria; central concealment of treatment 
assignment; excellent adherence to the first dose of allocated treatment; prospective 
collection of multiple functional outcomes as well as safety measures such as 
hypotension and hypertension; near-complete follow-up (96% of patients had their 
primary outcome recorded); and central, blinded assessment of outcomes at day 90. 
Patients received modern care including stroke unit admission, thrombolysis, 
thrombectomy, and hemicraniectomy. 
 
Several limitations are also present. First, GTN was administered in a single-blind 
design since there are no commercial sources of placebo patches. In spite of this, 
patient-blinding at day 90 was successful through use of a near identical sham patch, 
and both GTN and sham patches were unmarked; placement of a gauze dressing over 
the patch 8,9 10 gave additional blinding. Further, outcomes measured at day 90 were 
assessed centrally by trained staff masked to treatment assignment who were not 
involved in hospital care of enrolled patients. Second, many patients did not receive 
randomised treatment for the intended minimum period of two days, and even fewer 
for the full four days; hence, participants may have received inadequate treatment. 
Third, the difference in blood pressure between GTN and sham was small and less 
than that seen in the large ENOS trial.11,12 Whilst this might reflect inaccuracies in BP 
measurement in the emergency environment of ambulance and hospital admission, it 
might also explain the lack of benefit in ischaemic stroke. Fourth, we had to increase 
the sample size, an unplanned change necessary because of the higher-than-planned 
mimic rate. Last, the trial’s wide inclusion criteria recruited a population of stroke 
patients that would not normally enter hospital-based trials. In this respect, a group 
of participants with very severe ICH were enrolled who deteriorated rapidly and then 
died; this may have neutralised any treatment effect. 
 
So far as we are aware, this is the first acute stroke trial to use a hierarchical 
approach to analysis in which the first analysis in the primary family was performed in 
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the target population, with the potential for a subsequent primary analysis across the 
entire ITT population. We followed this pre-defined plan 17 since the high mimic rate 
had the potential to dilute out any treatment effect. Although the nonpositive result in 
the target population precluded testing the ITT population with multiplicity control, 
this approach had the advantage that the primary analysis of the study directly 
addressed the core question of biologic benefit of agent administration in patients with 
the disease of interest. 
 
In summary, treatment with transdermal GTN administered before hospital did not 
alter functional outcome in participants with ultra-acute stroke. The signals of 
potential adverse effect of GTN in ICH are not definitive, but suggest the advisability 
of close safety monitoring in ongoing trials of pre-hospital GTN in ultra-acute ICH 
(ISRCTN99503308). Nevertheless, earlier findings in the large ENOS trial, including in 
ICH, suggest that transdermal GTN is safe when administered later in hospital 11 and 
may continue to be used for lowering BP, for example prior to thrombolysis. Finally, 
the study shows that large ambulance-based studies are feasible in the UK and, by 
extrapolation and taking account of the FAST-MAG trial,15 to most developed 
countries. 
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Table 1. Baseline ambulance and hospital admission characteristics of patients enrolled in the RIGHT-2 trial, all stroke and TIA 
(cohort 1/target disease population) and all (cohort 2, intention-to-treat) patients. Data are number (%), median [IQR], or mean 
(standard deviation). 
 
Characteristic Confirmed stroke/TIA All  
 GTN Sham GTN Sham 
Ambulance data (pre-randomisation)     
Number of patients 434 418 568 581 
Consent by (%)     
   Participant 220 (51) 206 (49) 296 (52) 307 (53) 
   Relative, carer or friend 169 (39) 172 (41) 213 (38) 216 (37) 
   Paramedic 45 (10) 40 (10) 59 (10) 58 (10) 
Age (years) 73·7 (12·8) 75·3 (12·3) 72·3 (14·6) 72·7 (14·6) 
Sex, male (%) 234 (54) 220 (53) 294 (52) 300 (52) 
Time from onset to randomisation (minutes) 70 [45, 107] 70 [45, 110] 70 [45, 115] 72 [45, 118] 
ECG, AF/flutter (%) 81 (24) 77 (22) 92 (21) 95 (20) 
Systolic blood pressure (mmHg) 163·4 (24·5) 163·0 (24·9) 161·5 (24·7) 162·8 (25·5) 
Diastolic blood pressure (mmHg) 92·2 (19·1) 91·5 (17·8) 91·5 (18·5) 91·6 (17·2) 
Heart rate (bpm) 81·6 (18·7) 82·2 (18·6) 81·7 (18·0) 82·6 (19·2) 
Glasgow coma scale <14 (%) 123 (28) 106 (25) 162 (29) 140 (24) 
FAST score =3 (%) 276 (64) 270 (65) 343 (60) 347 (60) 
Hospital admission data (post randomisation)     
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Number of patients 434 418 568 581 
Ethnic group, non-white (%) 35 (8) 43 (10) 50 (9) 63 (11) 
Pre-morbid mRS >2 (%) 76 (18) 68 (16) 115 (20) 108 (19) 
Medical history (%)      
Hypertension 252 (58) 249 (60) 313 (56) 330 (58) 
Diabetes mellitus 82 (19) 86 (21) 109 (20) 118 (21) 
Previous stroke 100 (23) 87 (21) 137 (25) 135 (24) 
Ischaemic heart disease 66 (15) 72 (17) 95 (17) 101 (18) 
Smoking, current 63 (18) 51 (15) 89 (19) 79 (17) 
Qualifying event (%)     
   Ischaemic stroke 302 (70) 295 (71) 302 (53) 295 (51) 
   Intracerebral haemorrhage 74 (17) 71 (17) 74 (13) 71 (12) 
   Stroke type unknown 1 (0) 0 (0) 1 (<1) 0 (0) 
   TIA 57 (13) 52 (12) 57 (10) 52 (9) 
   Non-stroke/TIA mimic - - 134 (24) 163 (28) 
IQR: interquartile range; GTN: glyceryl trinitrate; AF: atrial fibrillation; bpm: beats per minute; FAST: face/arm/speech/time test; 
mRS: modified Rankin Scale; TIA: transient ischaemic attack 
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Table 2. Primary and secondary outcomes at days 4 and 90 in all stroke and TIA (cohort 1, modified intention-to-treat) and all 
(cohort 2, intention-to-treat) patients. Data are number (%), median [interquartile quartile range] or mean (standard deviation). 
Comparison by adjusted binary logistic regression (BLR), Cox proportional hazards regression (Cox), ordinal logistic regression 
(OLR), or multiple linear regression (MLR), with adjustment for age, sex, pre-morbid mRS, FAST score, pre-treatment systolic BP, 
index event (intracerebral haemorrhage, ischaemic stroke, transient ischaemic attack, mimic), time to randomisation, and 
reperfusion therapy (mechanical thrombectomy, alteplase, none) (unless stated). The effect of treatment for GTN versus sham are 
shown as odds ratio (OR), hazard ratio (HR), or difference in means (DIM), with 95% confidence intervals. 
 
  Cohort 1 mITT Confirmed 
stroke/TIA 
  Cohort 2 ITT All  
Outcome N 
852 
GTN 
N=434 
Sham 
N=418 
acOR/aOR/aDIM 
(95% CI) 
p N 
1149 
GTN 
N=568 
Sham 
N=581 
acOR/aOR/aDIM 
(95% CI) 
p 
Day 90 mRS (/6)           
Primary outcome 828 3 [2, 5] 3 [2, 5] 1·25 (0·97, 1·60) 0·083 1102 3 [2, 5] 3 [2, 5] 1·04 (0·84, 1·29) 0·69 
Sensitivity 
analyses 
          
Unadjusted 828 3 [2, 5] 3 [2, 5] 1·05 (0·83, 1·33) 0·70 1102 3 [2, 5] 3 [2, 5] 0·99 (0·81, 1·22) 0·96 
Mean 828 3·4 (2·0) 3·4 (1·9) 0·14 (-0·07, 0·36) 0·19 1102 3·2 (2·0) 3·2 (1·9) 0·01 (-0·17, 0·19) 0·92 
mRS>2 (%) 828 286 (68) 282 (69) 1·11 (0·79, 1·57) 0·55 1102 358 (66) 373 (67) 1·02 (0·76, 1·38) 0·88 
Per protocol 714 3 [2, 5] 3 [2, 5] 1·22 (0·93, 1·60) 0·14 959 3 [2, 5] 3 [2, 5] 1·05 (0·84, 1·33) 0·65 
Imputed 852 3 [2, 5] 3 [2, 5] 1·23 (0·96, 1·57) 0·10 1149 3 [2, 5] 3 [2, 5] 1·05 (0·85, 1·30) 0·65 
Hospital 
admission 
          
NIHSS (/42) 755 10·5 (7·6) 10·4 
(7·7) 
0·34 (-0·51, 1·19) 0·43 931 9·7 (7·6) 9·4 (7·5) 0·14 (-0·61, 0·89) 0·72 
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GCS (/15) 835 13·5 (2·3) 13·8 
(2·0) 
-0·37 (-0·64, -0·10) 0·007 1076 13·7 (2·2) 13·9 (1·9) -0·19 (-0·42, 0·04) 0·10 
FAST [/3]  799 2·3 (0·9) 2·2 (1·0) 0·09 (-0·02, 0·19) 0·10 985 2·2 (1·0) 2·1 (1·0) 0·03 (-0·07, 0·13) 0·51 
OCSP, TACS (%) 822 161 (38) 149 (37) 1·13 (0·82, 1·55) 0·45 1046 176 (34) 174 (33) 1·03 (0·78, 1·37) 0·83 
Day 4 (discharge)           
Death (%) 849 20 (5) 18 (4) 1·17 (0·57, 2·39) 0·68 1128 22 (4) 19 (3) 1·19 (0·60, 2·35) 0·63 
ND (%) a 534 60 (23) 56 (21) 1·14 (0·74, 1·77) 0·56 586 62 (21) 59 (20) 1·08 (0·70, 1·65) 0·73 
Headache (%) b 843 41 (10) 28 (7) 1·41 (0·84, 2·37) 0·19 1117 49 (9) 36 (6) 1·43 (0·90, 2·27) 0·13 
Hypotension (%) b 844 18 (4) 9 (2) 2·07 (0·90, 4·75) 0·085 1118 21 (4) 9 (2) 2·49 (1·11, 5·57) 0·026 
Hypertension (%) b 844 89 (21) 93 (22) 0·82 (0·57, 1·18) 0·28 1118 106 (19) 108 (19) 0·96 (0·69, 1·33) 0·81 
Feeding: non-oral 
(%) 
806 123 (30) 132 (33) 0·89 (0·63, 1·26) 0·51 1049 130 (25) 139 (26) 0·89 (0·65, 1·24) 0·50 
In hospital events           
Length of stay 847 17·4 (29·7) 19·1 
(28·9) 
-1·35 (-5·16, 2·46) 0·49 1126 14·6 (27·0) 15·3 (25·7) -1·09 (-4·00, 1·81) 0·46 
Died (%) 847 72 (17) 60 (14) 1·28 (0·84, 1·96) 0·26 1126 78 (14) 63 (11) 1·35 (0·90, 2·02) 0·15 
Died/institution (%) 831 180 (42) 167 (41) 1·17 (0·84, 1·61) 0·35 1102 193 (35) 186 (33) 1·08 (0·81, 1·46) 0·60 
Day 90           
Death (%) 841 97 (23) 79 (19) 1·24 (0·91, 1·68) 0·17 1122 105 (19) 98 (17) 1·11 (0·84, 1·47) 0·47 
Disposition (%) c 809 1 [1,2] 1 [1,2] 1·32 (0·96, 1·82) 0·086 1069 1 [1,2] 1 [1,2] 1·11 (0·83, 1·47) 0·48 
EQ-5D HSUV (/1) d 798 0·4 (0·4) 0·4 (0·4) -0·02 (-0·07, 0·03) 0·42 1055 0·4 (0·4) 0·4 (0·4) 0·00 (-0·04, 0·05) 0·95 
BI (/100) d 795 56·2 (45·0) 57·5 
(43·9) 
-2·74 (-7·82, 2·33) 0·29 1048 60·3 (43·7) 61·3 (43·1) -0·24 (-4·54, 4·06) 0·91 
TICS-M d e 439 12·4 (12·3) 13·2 
(12·1) 
-0·87 (-2·63, 0·90) 0·34 551 13·5 (12·3) 13·7 (11·8) 0·06 (-1·50, 1·63) 0·94 
ZDS (/100) d e 499 67·3 (29·7) 66·0 
(29·1) 
1·38 (-2·87, 5·63) 0·52 638 66·5 (28·8) 65·1 (28·6) 0·53 (-3·22, 4·28) 0·78 
Global outcome 
(MWD) 
828 - - -0·02 (-0·10, 0·06) 0·62 1102 - - 0·00 (-0·07, 0·06) 0·92 
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Home time (days) ‡ 682 55·8 (49·2) 55·5 
(46·8) 
-0·30 (-6·14, 5·54) 0·92 903 63·5 (48·9) 63·7 (46·9) 2·18 (-2·81, 7·16) 0·39 
 
BI: Barthel index; DIM: difference in means; FAST: face/arm/speech/time test (calculated from NIHSS); EQ-5D: Euro-Quality of 
life-5 Dimensions; EQ-VAS: Euro-Quality of life-Visual Analogue Scale; HSUV: health status utility value (calculated from EQ-5D); 
mRS: modified Rankin scale; ND: neurological deterioration; NIHSS: National Institutes of Health Stroke Scale; OCSP: Oxford 
Community Stroke Project; TACS: total anterior circulation syndrome (in IS and ICH); TIA: transient ischaemic attack; TICS-M: 
modified telephone interview cognition scale; t-MMSE: telephone mini-mental state examination; ZDS: Zung depression scale; 
MWD: Mann-Whitney difference 
a Neurological deterioration from hospital admission: NIHSS >=4 points or >=2 point increase in any domain 
b Clinical 
c Disposition: home, institution/in hospital, died. 
d Death scored as: BI -5, verbal fluency (animal naming) -1, EQ-VAS -1, home time -1, t-MMSE -1, TICS-M -1, EQ-5D HSUV 0, 
GCS 2, mRS 6, NIHSS 43, ZDS 102·5 
e Incomplete TICS-M and ZDS due to inability by participants with severe stroke to respond to questions 
The per protocol population is defined in the Appendix. 
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Figure 1. Consort flow diagram of patient randomisation, outcome, and losses to 
follow-up for all patients (cohort 2, intention-to-treat). Data are number (%) 
 
 
  
RIGHT-2 CONFIDENTIAL 13/1/19 Version 1.53 
 Page 36 of 38 
 
Figure 2. Distribution of modified Rankin Scale (mRS) at day 90 for glyceryl trinitrate 
(GTN) versus sham, in stroke/TIA patients (cohort 1, modified intention-to-treat). 
Comparison by ordinal logistic regression adjusted for age, sex, pre-morbid mRS, 
FAST score, pre-treatment systolic BP, index event (intracerebral haemorrhage, 
ischaemic stroke, transient ischaemic attack, mimic) and time to randomisation. 
 
Adjusted common odds ratio 1·25 (95% confidence intervals 0·97, 1·60), p=0·083 
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Figure 3. Forest plot of effect of GTN versus Sham on mRS at day 90 in stroke and 
TIA patients in pre-specified subgroups defined before treatment and admission to 
hospital. Data are odds ratio (95% confidence intervals) and interaction test. 
Comparison by ordinal logistic regression adjusted for age, sex, pre-morbid mRS, 
FAST, pre-treatment systolic BP, index event (intracerebral haemorrhage, ischaemic 
stroke, transient ischaemic attack, mimic), time to randomisation and reperfusion 
therapy (alteplase, intra-arterial therapy, none). 
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